Compare AYI & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AYI | CYTK |
|---|---|---|
| Founded | 2001 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 10.7B |
| IPO Year | 2001 | 2004 |
| Metric | AYI | CYTK |
|---|---|---|
| Price | $339.61 | $78.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 19 |
| Target Price | ★ $369.17 | $89.26 |
| AVG Volume (30 Days) | 252.5K | ★ 1.8M |
| Earning Date | 04-02-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 11.45 | N/A |
| Revenue | ★ $3,461,000,000.00 | $13,368,000.00 |
| Revenue This Year | $7.51 | $7.37 |
| Revenue Next Year | $5.14 | $310.19 |
| P/E Ratio | $29.40 | ★ N/A |
| Revenue Growth | ★ 4.05 | N/A |
| 52 Week Low | $257.04 | $35.22 |
| 52 Week High | $380.17 | $88.31 |
| Indicator | AYI | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 48.79 | 51.75 |
| Support Level | $335.50 | $78.27 |
| Resistance Level | $375.91 | $79.66 |
| Average True Range (ATR) | 7.89 | 2.47 |
| MACD | -2.57 | 0.22 |
| Stochastic Oscillator | 20.08 | 60.42 |
Acuity is a leading industrial technology company that offers lighting, lighting controls, and intelligent building solutions. It designs, manufactures, and brings to market products and services relating to these and other offerings. Acuity has two reportable segments: Acuity Brands Lighting and Acuity Intelligent Spaces. ABL sells commercial, architectural, and specialty lighting, including components and control systems. AIS offers building management and audio/visual solutions to help make buildings intelligent.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.